


## LE 300

<b>Cat. No.:</b>	HY-103428
<b>CAS No.:</b>	274694-98-3
<b>Molecular Formula:</b>	C <sub>20</sub> H <sub>22</sub> N <sub>2</sub>
<b>Molecular Weight:</b>	290.4
<b>Target:</b>	Dopamine Receptor; 5-HT Receptor
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	LE 300 is a potent and selective dopamine D <sub>1</sub> -like receptor antagonist with K <sub>i</sub> s of 1.9 nM and 7.5 nM in CHO cell membranes expressing human dopamine D <sub>1</sub> and D <sub>5</sub> receptors, respectively. LE 300 is an antagonist of the 5-HT <sub>2A</sub> receptor with a pA <sub>2</sub> of 8.32 in a rat tail artery assay <sup>[1][2]</sup> .		
<b>IC<sub>50</sub> &amp; Target</b>	Human D <sub>1</sub> Receptor 1.9 nM (K <sub>i</sub> )	Human D <sub>5</sub> Receptor 7.5 nM (K <sub>i</sub> )	Rat 5-HT <sub>2A</sub> 8.32 (pA <sub>2</sub> )

## REFERENCES

[1]. Kassack MU, et al. Pharmacological characterization of the benz[d]indolo[2,3-g]azecine LE300, a novel type of a nanomolar dopamine receptor antagonist. *Naunyn Schmiedebergs Arch Pharmacol.* 2002 Dec;366(6):543-50.

[2]. Rostom SA. Novel fused pyrrole heterocyclic ring systems as structure analogs of LE 300: Synthesis and pharmacological evaluation as serotonin 5-HT<sub>2A</sub>, dopamine and histamine H(1) receptor ligands. *Arch Pharm (Weinheim).* 2010 Feb;343(2):73-80.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA